Approved Study Database
| Ref. No. | Scientific Title | Principal investigator |
|---|---|---|
| 2010.056 | Effect of anti-TNF | Professor TAM LAI SHAN |
| 2013.568 | A 48 weeks, phase II, randomized, double-blind, placebo-controlled, proof of concept and dose finding study of three different dose regimens of BI 655066 administered subcutaneously in patients with ankylosing spondylitis. | Prof. TAM Lai Shan |
| 2013.470 | A multi-center, uncontrolled extension study evaluating efficacy and safety of SAR153191 on top of DMARDs in patients with active Rheumatoid Arthritis (RA) | Prof Tam Lai Shan |
| 2011.483 | Effect of treat-to-target strategies aiming at remission compared with minimal disease activity on arterial stiffness in early rheumatoid arthritis - a randomized controlled study | Prof. TAM Lai Shan |
| 2007.486 | A Double-blind, Randomized, Placebo-control Trial to Assess the Effects of Hydroxychloroquine on Progression of Carotid Artery Intimal-Medial Thickening in Psoriatic Arthritis | Ms Tam Lai Shan |
| 2012.557 | A Randomized, Double-Blind, Placebo-Controlled 52-Week Study to Assess Adverse Events of Special Interest in Adults with Active, Autoantibody-Positive Systemic Lupus Erythematosus Receiving Belimumab | Prof. TAM Lai Shan |
| 2008.343 | The Chinese University of Hong Kong Early Arthritis Study | Prof Tam Lai Shan |
| 2008.344 | Premature Atherosclerosis in Early Rheumatoid Arthritis | Prof Tam Lai Shan |
| 2012.559 | A randomized, double-blind, parallel, placebo-controlled study assessing the efficacy and safety of sarilumab added to non-biologic DMARD therapy in patients with rheumatoid arthritis who are inadequate responders to or intolerant of TNF-α antagonists | Prof. TAM Lai Shan |
| 2012.558 | An adaptive Phase II study to evaluate the efficacy, pharmacodynamics, safety and tolerability of GSK2586184 in patients with mild to moderate systemic lupus erythematosus | Professor Tam Lai Shan |
| 2008.391 | A Multi-Center, Continuation Trial of Belimumab (HGS1006, LymphoStat-B™), A Fully Human Monoclonal Anti-BLyS Antibody, in Subjects with Systemic Lupus Erythematosus (SLE) who Completed the Phase 3 Protocol HGS1006-C1056 or HGS1006-C1057 | Prof. TAM Lai Shan |
| 2016.366 | MicroRNAs as biomarkers for predicting the effect of anti-TNF and anti-IL6 in changes of bone erosions in rheumatoid arthritis using HR-pQCT |
Prof. TAM Lai Shan 譚麗珊 |
| 2017.261 | The impact of nurse-led programme with and without statin treatment base on traditional cardiovascular risk score or carotid ultrasound on addressing cardiovascular risk in patients with arthritis: a prospective, multicentre, randomised, controlled trial | Prof. TAM Lai Shan |
| 2017.605 | Evaluation of molecular and cellular dysregulation in systemic lupus erythematosus | Prof. TAM Lai Shan |
| 2017.295 | The long term renal outcome of biopsy proven paediatric lupus nephritis - a comparison of local and overseas cohort |
Prof. TAM Lai Shan 譚麗珊 |
| 2016.451 | Prevention of metacarpophalangeal joints structure damage in patients with psoriatic arthritis using secukinumab |
Prof. TAM Lai Shan 譚麗珊 |
| 2016.450 | Cost Effectiveness Analysis of Biologic Therapies for the Treatment of Rheumatoid Arthritis in Hong Kong |
Prof. TAM Lai Shan 譚麗珊教授 |
| 2016.359 | A double-blind, randomised, placebo-controlled trial evaluating the effect of BI 655064 administered as sub-cutaneous injections, on renal response after one year of treatment, in patients with active lupus nephritis |
Prof. TAM Lai Shan 譚麗珊教授 |
| 2017.146 | Circulating microRNAs as biomarkers for predicting the early development, repair and progression of bone erosions in early rheumatoid arthritis using HR-pQCT |
Prof. TAM Lai Shan 譚麗珊 |
| 2016.037 | Identification and validation of microRNAs associated with inflammation detected by magnetic resonance imaging in patients with early rheumatoid arthritis. |
Prof. TAM Lai Shan 譚麗珊 |
| 2013.469 | The Clinical Rheumatology Systematic Treat-to-target in Asia Leadership (CRYSTAL) Project | Prof. TAM Lai Shan |
| 2017.633 | An exploratory maintenance trial evaluating the effect of BI 655064 in Lupus Nephritis patients who have achieved a meaningful response either at the end of 1293.10 or after an induction treatment outside of 1293.10 |
Prof. TAM Lai Shan 譚麗珊教授 |
| 2015.214 | Prevalence and risk factors for osteoporosis in patients with ankylosing spondylitis in Hong Kong: a cross-sectional cohort study |
Dr. TAM Lai Shan 譚麗珊 |
| 2016.431 | Effect of RANKL inhibition on healing of bone erosion in rheumatoid arthritis using HR-pQCT |
Prof. TAM Lai Shan 譚麗珊 |
| 2014.343 | Adaptation and validation of the Ankylosing Spondylitis Quality of Life (ASQOL) and Psoriatic Arthritis Quality of Life (PsAQOL) questionnaires in Hong Kong | Prof. TAM Lai Shan |
| 2013.451 | Immunopathological roles of the novel inflammatory cytokine interleukin-36 in the patients with systemic lupus erythematous | Professor TAM Lai Shan |
| 2017.389 | A Phase 3, Randomized, Double-Blind, Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Subjects with Active Psoriatic Arthritis Who Have a History of Inadequate Response to at Least One Non-Biologic Disease Modifying Anti-Rheumatic Drug (DMARD) – SELECT – PsA 1 | Prof. TAM Lai Shan |
| 2014.387 | Coronary atherosclerosis in psoriatic arthritis | Prof. TAM Lai Shan |
| 2015.334 | Characterization of the potential role of interleukin-36 (IL-36) in regulating protective and pathogenic B cells in systemic lupus erythematosus |
Dr. TAM Lai Shan 譚麗珊 |
| 2016.390 | Assessment of structure changes after 4 years on the second and third metacarpophalangeal joint and distal radius in patients with psoriatic arthritis – a follow-up study using High-resolution peripheral quantitative CT (HR-pQCT) |
Prof. TAM Lai Shan 譚麗珊 |
| 2013.300 | Immunopathological roles of the novel anti-inflammatory cytokine interleukin-35 in the patients with systemic lupus erythematous | Professor TAM Lai Shan |
| 2017.446 | A Multicenter, Open-label, Long Term Extension Study to Assess the Safety and Efficacy of Filgotinib in Subjects with Rheumatoid Arthritis |
Prof. TAM Lai Shan 譚麗珊 |
| 2015.697 | Freely circulating microRNAs as biomarkers for fracture and bone loss in female patients with systemic lupus erythematosus on long-term glucocorticoid therapy |
Prof. TAM Lai Shan 譚麗珊 |
| 2017.683 | Calprotectin in psoriatic arthritis |
Prof. TAM Lai Shan 譚麗珊 |
| 2016.551 | A Randomized Open-label Study to Evaluate the Efficacy and Safety of Tacrolimus and Corticosteroids in Comparison with Mycophenolate Mofetil and Corticosteroids in Subjects with Class III/IV±V Lupus Nephritis |
Prof. TAM Lai Shan 譚麗珊 |
| 2015.664 | A Phase 3, Randomized, Double-Blind Study Comparing Upadacitinib (ABT-494) to Placebo in Subjects with Moderately to Severely Active Rheumatoid Arthritis Who Are on a Stable Dose of Conventional Synthetic Disease-Modifying Anti-Rheumatic Drugs (csDMARDs) and Have an Inadequate Response to csDMARDs |
Prof. TAM Lai Shan 譚麗珊 |
| 2017.239 | The Hong Kong Psoriatic Arthritis Screening program | Prof. TAM Lai Shan |
| 2017.700 | Circulating microRNA 99b as biomarker for predicting the early development, repair and progression of bone erosions in early rheumatoid arthritis using HR-pQCT |
Prof. TAM Lai Shan 譚麗珊 |
| 2015.065 | Phase 3b/4 Randomized Safety Endpoint Study Of 2 Doses Of Tofacitinib In Comparison To A Tumor Necrosis Factor (TNF) Inhibitor In Subjects With Rheumatoid Arthritis | Prof. TAM Lai Shan |
| 2016.533 | A Randomized, Double-blind, Placebo- and Active-controlled, Multicenter, Phase 3 Study to Assess the Efficacy and Safety of Filgotinib Administered for 52 weeks in Combination with Methotrexate to Subjects with Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Methotrexate |
Prof. TAM Lai Shan 譚麗珊 |
| 2011.547 | The role of Receptor for Advanced Glycation End Products (RAGE) in the pathogenesis of systemic Lupus erythematosus (SLE) | Professor TAM Lai Shan |
| 2012.478 | Vascular effects of achieving minimal disease activity iin psoriatic arthritis - a 2 year prospetive cohort study | Prof. TAM Lai Shan |
| 2010.250 | HMGB1: a danger signal molecule of the innate immune response for the immunopathogenesis of systemic lupus erythematosus | Professor TAM Lai Shan |
| 2014.052 | Advanced 3-D Bioimaging Technology to improve vertebral fracture prediction in patients with glucocorticoid-induced osteoporosis | Prof. TAM Lai Shan |
| 2009.583 | Function and expression profile of the nucleotide-blinding and oligoerization domain (NOD)-2 receptors in systemic lupus erythematosus | Prof Tam Lai Shan |
| 2008.475 | Innate pathogen recognition in systemic lupus erythematosus: Toll-like receptors and NOD-like receptors | Prof Tam Lai Shan |
| 2011.031 | The role of HMGB1 in the pathogenesis of systemic lupus erythematosus | Professor TAM Lai Shan |
| 2010.191 | Human Papillomavirus infection and cervical intraepithelial neoplasia in patients with systemic lupus erythematosus- the role of toll-like receptors | Professor TAM Lai Shan |
| 2018.417 | Prevention of metacarpophalangeal joints structure damage in patients with psoriatic arthritis using tofacitinib | Prof. TAM Lai Shan |
| 2019.264 | Incidence of and associated factors of infective complications in rheumatology patients taking DMARDs | Dr. TAM Lai Shan |
Page 200 of 262.